A recent phase I trial of convection-enhanced delivery of an IL13-targeted exotoxin for H3K27-mutant diffuse midline glioma used the 43-item Impact of Pediatric Illness (IPI) Parent Report Form to record health-related QOL in five pediatric patients [10]. The gene discussed is IL13; the disease is diffuse midline glioma.